Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Dise
Go back to Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Dise| (NASDAQ: PVLA) | Delayed: 119.07 +5.97 (5.28%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $113.10 | 52 Week High | $ | |||
| Open | $115.29 | 52 Week Low | $ | |||
| Day High | $120.88 | P/E | N/A | |||
| Day Low | $114.55 | EPS | $ | |||
| Volume | 113,554 | |||||
